19 results on '"Cowen, Philip J."'
Search Results
2. Subchronic treatment with St John's wort produces a positive shift in emotional processing in healthy volunteers.
- Author
-
Warren, Matthew B., Cowen, Philip J., and Harmer, Catherine J.
- Subjects
- *
ANTIDEPRESSANTS , *MENTAL depression , *HYPERICUM , *CLINICAL trials , *SHORT-term memory , *COGNITION , *EMOTIONS , *HYPERICUM perforatum , *PLANT extracts , *BLIND experiment , *PHARMACODYNAMICS - Abstract
Background: The neurocognitive model of antidepressant treatment in depression states that antidepressants work by producing relatively immediate positive shifts in emotional processing, which translate into clinical improvement with time. St John's Wort has shown antidepressant potential in randomised controlled trials; however, its pharmacological actions are broad and it is unknown whether treatment also produces changes in emotional processing.Aims: We investigated whether short-term treatment with St John's wort has similar effects on emotional processing to those reported with other antidepressants such as selective serotonergic reuptake inhibitors.Methods: Forty-eight healthy participants were given St John's wort or placebo treatment for seven days. On day 7 they completed a battery of tasks to measure emotional processing and other elements of cognition.Results: St John's wort treatment produced similar changes to other antidepressants, for example reducing recognition of disgusted faces and attention to fearful faces, while increasing memory for positive words. We failed to find evidence for an effect of St John's wort on other aspects of cognition including working memory.Conclusions: These findings lend support to the theory that the production of early positive biases in emotional processing may be a common feature of all clinically effective antidepressants with diverse pharmacological mechanisms. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
3. Neuroendocrine and Neurochemical Processes in Depression.
- Author
-
Cowen, Philip J
- Subjects
- *
AMINO acid neurotransmitters , *KETAMINE abuse , *HYPOTHALAMIC-pituitary-adrenal axis , *MENTAL depression , *DEPRESSED persons , *METHYL aspartate receptors - Abstract
Neuroendocrine and neurochemical theories of depression continued to be of importance in understanding pathophysiology and suggesting new kinds of pharmacological intervention. Monoamine theories still dominate the neurochemistry of depression and results from monoamine depletion studies suggest that in certain circumstances lowered activity of serotonin and noradrenaline pathways can indeed lead to clinical depressive symptomatology. More recent developments have implicated changes in the amino acid neurotransmitters, GABA and glutamate, in depressed patients; the ability of the NMDA receptor antagonist, ketamine, rapidly to relieve depressive symptomatology has been a spur to much basic research on the cellular mechanism of glutamatergic antidepressant action. The link between inflammation and depression has led to new kinds of immunological investigations in depressed patients and the possibility of targeted anti-inflammatory treatments. Finally HPA axis abnormalities remain a focus of interest, particularly from the point of view of the many medical co-morbidities which frequently complicate chronic depressive disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
4. Efficacy markers in depression.
- Author
-
Harmer, Catherine J, Cowen, Philip J, and Goodwin, Guy M
- Subjects
- *
MENTAL depression , *DEPRESSED persons , *ANTIDEPRESSANTS , *DRUG development , *EMOTIONS - Abstract
Current antidepressant agents are similar in efficacy to the original drugs discovered in the 1950s. The development of new treatments for depression is, however, limited by the absence of validated human biomarker models to predict efficacy, clinical profile and dosing. Such models need to meet key criteria for biomarkers including sensitivity, specificity and relevance to depression. Here we review studies exploring whether early changes in emotional processing with antidepressant drug administration meet these criteria. A large body of evidence suggests that changes in emotional memory are particularly relevant to depression and to antidepressant drug action whereas changes in attentional processing are sensitive to anxiolytic drugs. These tasks are not consistently affected by agents which have failed in clinical trials in depression, but do show changes in the predicted direction with agents associated either with amelioration or induction of symptoms. Hence, early assessment of novel drugs on emotional processing may predict likely clinical effects and dosing prior to randomized controlled trials. Greater validation is required to assess whether these effects are an obligatory component of effective treatment of depression and whether use of these models can improve the accuracy of go/no-go decisions in drug development. [ABSTRACT FROM PUBLISHER]
- Published
- 2011
- Full Text
- View/download PDF
5. Overnight transdermal scopolamine patch administration has no clear effect on cognition and emotional processing in healthy volunteers.
- Author
-
Bukala, Bernard R., Browning, Michael, Cowen, Philip J., Harmer, Catherine J., and Murphy, Susannah E.
- Subjects
- *
SCOPOLAMINE , *MENTAL depression , *ANTIDEPRESSANTS , *SHORT-term memory , *EMOTIONAL intelligence - Abstract
There has been increasing interest in the antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine. Here we assess, for the first time, whether a transdermal scopolamine patch is sufficient to induce changes in cognition that are consistent with the reported cognitive and antidepressant effects of scopolamine. A scopolamine or placebo patch was administered to healthy volunteers ( n=33) for 17 h in a double-blind, between-subject procedure. There was no clear effect of scopolamine patch on emotional cognition, verbal or working memory, suggesting that the effective dose of scopolamine available through the patch is too low to represent a viable antidepressant mechanism. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
6. Tianeptine in an experimental medicine model of antidepressant action.
- Author
-
Cooper, Charlotte M, Whiting, Daniel A, Cowen, Philip J, and Harmer, Catherine J
- Subjects
- *
EXPERIMENTAL medicine , *NEUROPSYCHOLOGY , *SEROTONIN , *DRUG efficacy , *THERAPEUTICS ,PHYSIOLOGICAL effects of antidepressants - Abstract
Changes in emotional processing have been shown following acute administration of a range of monoaminergic antidepressants, and may represent an important common neuropsychological mechanism underpinning their therapeutic effects. Tianeptine is an agent that challenges the traditional monoaminergic hypothesis of antidepressant action, though its exact mode of action remains controversial. Healthy volunteers were randomised to receive a single dose of tianeptine (12.5 mg) or placebo, and subsequently completed a battery of tasks measuring emotional processing, including facial expression recognition, emotional memory and attentional vigilance, as well as working and verbal memory. Tianeptine-treated subjects were less accurate at identifying facial expressions, though this was not valence specific. The tianeptine group also showed reduced positive affective memory and reduced attentional vigilance to positive stimuli. There were no effects on emotional categorization or non-emotional cognition. The negative biases in aspects of emotional processing observed following acute tianeptine administration are at variance with the positive biases generally seen after acute administration of conventional antidepressant drugs, despite tianeptine’s putative antidepressant efficacy. This is an intriguing finding in the context of the lack of consensus regarding tianeptine’s mechanism of action; however, it may be consistent with the reported ability of acute tianeptine to increase the re-uptake of serotonin. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
7. The effects of atorvastatin on emotional processing, reward learning, verbal memory and inflammation in healthy volunteers: An experimental medicine study.
- Author
-
De Giorgi, Riccardo, Martens, Marieke, Rizzo Pesci, Nicola, Cowen, Philip J, and Harmer, Catherine J
- Subjects
- *
REWARD (Psychology) , *EXPERIMENTAL medicine , *VERBAL memory , *ATORVASTATIN , *EMOTIONAL conditioning , *NEUROPSYCHOLOGY , *ANTIDEPRESSANTS , *VERBAL learning , *ANTILIPEMIC agents - Abstract
Background: Growing evidence from clinical trials and epidemiological studies suggests that statins can have clinically significant antidepressant effects, potentially related to anti-inflammatory action on several neurobiological structures. However, the underlying neuropsychological mechanisms of these effects remain unexplored. Aims: In this experimental medicine trial, we investigated the 7-day effects of the lipophilic statin, atorvastatin on a battery of neuropsychological tests and inflammation in healthy volunteers. Methods: Fifty healthy volunteers were randomised to either 7 days of atorvastatin 20 mg or placebo in a double-blind design. Participants were assessed with psychological questionnaires and a battery of well-validated behavioural tasks assessing emotional processing, which is sensitive to putative antidepressant effects, reward learning and verbal memory, as well as the inflammatory marker, C-reactive protein. Results: Compared to placebo, 7-day atorvastatin increased the recognition (p = 0.006), discriminability (p = 0.03) and misclassifications (p = 0.04) of fearful facial expression, independently from subjective states of mood and anxiety, and C-reactive protein levels. Otherwise, atorvastatin did not significantly affect any other psychological and behavioural measure, nor peripheral C-reactive protein. Conclusions: Our results reveal for the first time the early influence of atorvastatin on emotional cognition by increasing the processing of anxiety-related stimuli (i.e. increased recognition, discriminability and misclassifications of fearful facial expression) in healthy volunteers, in the absence of more general effects on negative affective bias. Further studies exploring the effects of statins in depressed patients, especially with raised inflammatory markers, may clarify this finding and inform future clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. When Helping Is Risky: The Behavioral and Neurobiological Trade-off of Social and Risk Preferences.
- Author
-
Gross, Jörg, Faber, Nadira S., Kappes, Andreas, Nussberger, Anne-Marie, Cowen, Philip J., Browning, Michael, Kahane, Guy, Savulescu, Julian, Crockett, Molly J., and De Dreu, Carsten K. W.
- Subjects
- *
HELPING behavior in children , *DECISION making , *NEUROTRANSMITTERS , *INDIVIDUALS' preferences , *RISK-taking behavior , *HEALTH behavior - Abstract
Helping other people can entail risks for the helper. For example, when treating infectious patients, medical volunteers risk their own health. In such situations, decisions to help should depend on the individual's valuation of others' well-being (social preferences) and the degree of personal risk the individual finds acceptable (risk preferences). We investigated how these distinct preferences are psychologically and neurobiologically integrated when helping is risky. We used incentivized decision-making tasks (Study 1; N = 292 adults) and manipulated dopamine and norepinephrine levels in the brain by administering methylphenidate, atomoxetine, or a placebo (Study 2; N = 154 adults). We found that social and risk preferences are independent drivers of risky helping. Methylphenidate increased risky helping by selectively altering risk preferences rather than social preferences. Atomoxetine influenced neither risk preferences nor social preferences and did not affect risky helping. This suggests that methylphenidate-altered dopamine concentrations affect helping decisions that entail a risk to the helper. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Effects of acute tyrosine depletion on subjective craving and selective processing of smoking-related cues in abstinent cigarette smokers.
- Author
-
Munafò, Marcus R., Mannie, Zota N., Cowen, Philip J., Harmer, Catherine J., and McTavish, Sarah B.
- Subjects
- *
TYROSINE , *SMOKING , *CIGARETTE smokers , *DOPAMINE , *NEURAL transmission - Abstract
We investigated the impact of the administration of a tyrosine-depleting amino acid mixture compared to a balanced mixture on measures of mood, craving and selective processing of smoking-related cues in healthy cigarette smokers instructed to abstain from smoking for 12 h prior to, and during, the experiment. A modified Stroop task was used to index selective processing of smoking-related cues. We observed evidence for an increase in subjective craving among mates, and an attenuation of the selective processing of smoking-related cues compared to control cues among females, in the tyrosine-depleting condition compared to the balanced condition. No effects of mixture were observed on measures of subjective mood. These results tentatively support for the rote of dopaminergic neurotransmission in mediating the response of cigarette smokers to smoking-related cues. In addition, these results also provide further evidence for sex differences in the factors that maintain cigarette smoking, in particular with respect to conditioned reinforcement of smoking behaviour, and suggest that the relationship between subjective craving and selective processing of smoking-related cues may differ in mates and females. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
10. Effects of alpha-lactalbumin on emotional processing in healthy women.
- Author
-
Scrutton, Helen, Carbonnier, Anne, Cowen, Philip J, and Harmer, Catherine J
- Subjects
- *
AFFECT (Psychology) , *AMINO acids , *CASEINS , *COGNITION , *COMPARATIVE studies , *EMOTIONS , *FACIAL expression , *HYDROCORTISONE , *RESEARCH methodology , *MEDICAL cooperation , *MEMORY , *ORAL drug administration , *DIETARY proteins , *REFERENCE values , *RESEARCH , *SALIVA , *TRYPTOPHAN , *VISUAL perception , *EVALUATION research - Abstract
The synthesis of serotonin (5-HT) in the central nervous system is dependent on the availability to the brain of its precursor amino acid, tryptophan (TRP). Recent studies suggest that alpha-lactalbumin, a whey-derived protein with a relatively high TRP content, increases plasma TRP and produces endocrine and cognitive changes consistent with facilitation of brain 5-HT function. In the present study we assessed the biochemical and cognitive effects of alpha-lactalbumin (40 g) in 28 healthy female subjects in a parallel group, placebo-controlled design. Relative to a casein-derived control protein, alpha-lactalbumin increased plasma TRP and the ratio of TRP to neutral amino acids. However, there was no effect on salivary cortisol secretion or tasks of emotional processing shown previously to be sensitive to pharmacological manipulation of 5-HT in healthy volunteers. The results suggest that alpha-lactalbumin produces a relatively modest increase in TRP availability which may not be sufficient to produce the changes in emotional processing seen with administration of pure TRP in healthy subjects. Further studies in subjects more vulnerable to stress are needed to assess the potential therapeutic effects of alpha-lactalbumin in clinical populations. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
11. Effects of α-lactalbumin on emotional processing in healthy women.
- Author
-
Scrutton, Helen, Carbonnier, Anne, Cowen, Philip J., and Harmer, Catherine J.
- Subjects
- *
WOMEN'S health , *PSYCHOPHARMACOLOGY , *TRYPTOPHAN , *CASEINS , *SEROTONIN , *HYDROCORTISONE - Abstract
The synthesis of serotonin (5-HT) in the central nervous system is dependent on the availability to the brain of its precursor amino acid, tryptophan (TRP). Recent studies suggest that α-lactalbumin, a whey derived protein with a relatively high TRP content, increases plasma TRP and produces endocrine and cognitive changes consistent with facilitation of brain 5-HT function. In the present study we assessed the biochemical and cognitive effects of α-lactalbumin (40g) in 28 healthy female subjects in a parallel group, placebo-controlled design. Relative to a casein-derived control protein, α-lactalbumin increased plasma TRP and the ratio of TRP to neutral amino acids. However, there was no effect on salivary cortisol secretion or tasks of emotional processing shown previously to be sensitive to pharmacological manipulation of 5-HT in healthy volunteers. The results suggest that α-lactalbumin produces a relatively modest increase in TRP availability which may not be sufficient to produce the changes in emotional processing seen with administration of pure TRP in healthy subjects. Further studies in subjects more vulnerable to stress are needed to assess the potential therapeutic effects of α-lactalbumin in clinical populations. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
12. Validation of a tracer kinetic model for the quantification of 5-HT2A receptors in human brain with [11C]MDL 100,907.
- Author
-
Hinz, Rainer, Bhagwagar, Zubin, Cowen, Philip J., Cunningham, Vincent J., and Grasby, Paul M.
- Subjects
- *
POSITRON emission tomography , *SEROTONIN , *ANTIDEPRESSANTS , *COMPUTER-aided diagnosis , *NEUROTRANSMITTERS , *PSYCHIATRIC drugs - Abstract
The positron emission tomography (PET) ligand [11C]MDL 100,907 has previously been introduced to image the serotonin 2A (5-HT2A) receptor in human brain. The aim of this work was to contribute to the verification of the tracer kinetic modelling in human studies. Five healthy volunteers were scanned twice after intravenous bolus injection of approximately 370 MBq [11C]MDL 100,907 using dynamic PET. One scan was performed under baseline condition, the other scan commenced 90 mins after a single oral dose of 30 mg of the antidepressant mirtazapine, which binds to the 5-HT2A receptor. There did not appear to be radiolabelled metabolites of [11C]MDL 100,907 in human plasma, which are likely to cross the blood–brain barrier. Total volumes of distribution VD in 11 different brain regions were estimated using a reversible, two tissue, four rate constants compartment model with a variable fractional blood volume term and the metabolite-corrected plasma input function. There were no significant changes of the VD in the cerebellum between the baseline and the blocked scans confirming the cerebellum as a region devoid of displaceable binding. Regional estimates of binding potential were then obtained indirectly using the cerebellar VD and occupancies calculated. The mean occupancy with this clinically effective dose of mirtazapine was 60% without significant regional differences. This study confirmed the use of an arterial input kinetic model for the quantification of 5-HT2A receptor binding with [11C]MDL 100,907 and the use of the cerebellum as a reference region for the free and nonspecific binding.Journal of Cerebral Blood Flow & Metabolism (2007) 27, 161–172. doi:10.1038/sj.jcbfm.9600323; published online 10 May 2006 [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
13. Antidepressants, withdrawal, and addiction; where are we now?
- Author
-
Jauhar, Sameer, Hayes, Joseph, Goodwin, Guy M, Cowen, Philip J, Baldwin, David S, and Nutt, David J
- Subjects
- *
SEROTONIN uptake inhibitors , *ANTIDEPRESSANTS , *ADDICTIONS , *KNOWLEDGE gap theory , *DEBATE , *COMPARATIVE studies , *COMPULSIVE behavior , *DRUG withdrawal symptoms , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *EVALUATION research - Abstract
Controversy continues with regard to antidepressants and withdrawal. Recent debates have focused on the prevalence and length of withdrawal, and some continue to state that withdrawal from these compounds constitutes 'addiction'. In this editorial we examine the evidence underlying these recent debates. We acknowledge gaps in knowledge, and make suggestions for how the field can progress. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. The putative lithium-mimetic ebselen reduces impulsivity in rodent models.
- Author
-
Barkus, Chris, Ferland, Jacqueline-Marie N., Adams, Wendy K., Churchill, Grant C., Cowen, Philip J., Bannerman, David M., Rogers, Robert D., Winstanley, Catharine A., and Sharp, Trevor
- Subjects
- *
IMPULSE control disorders , *BIPOLAR disorder , *AFFECTIVE disorders , *MENTAL illness , *PSYCHOLOGY , *NEUROPROTECTIVE agents - Abstract
Background: Deficits in impulse control feature in many psychiatric conditions including bipolar disorder, suicidality and addictions. Lithium lowers impulsivity in clinical populations and decreases pathological gambling in experimental medicine studies, but suffers from adverse effects, poor compliance and a low therapeutic index.Aims: Recently we identified that the neuroprotective agent ebselen, which is reportedly safe in humans, inhibited inositol monophosphatase (IMPase), a candidate lithium mechanism. Ebselen also reduced 5-HT receptor (5-HT2A) function which predicts impulsivity lowering properties. Here we investigated the effect of ebselen in rat models of impulsive behaviour.Methods: Ebselen was tested in two models of impulsivity with human analogues: the five-choice serial reaction time task (5-CSRTT) and rodent gambling task (rGT). The main outcome measures were premature responses (5-CSRTT and rGT) and choice behaviour (rGT), which model motor impulsivity and choice impulsivity, respectively.Results: At doses that decreased 5-HT2A receptor function (DOI-induced wet dog shakes), ebselen decreased premature responding in the 5-CSRTT both in the absence and presence of cocaine. The 5-HT2A receptor antagonist MDL 100,907 also reduced premature responding in the 5-CSRTT although not in the presence of cocaine. In the rGT ebselen showed a tendency to reduce premature responding but had no effect on choice behaviour.Conclusions: These findings suggest that ebselen preferentially reduces motor impulsivity over choice impulsivity, and that inhibition of 5-HT2A receptor function is a contributing mechanism. Collectively, these data support the repurposing of ebselen as an anti-impulsive treatment and fast-tracking to clinical trials in patient groups characterised by poor impulse control. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
15. Does melatonin treatment change emotional processing? Implications for understanding the antidepressant mechanism of agomelatine.
- Author
-
Pringle, Abbie, Bogdanovskaya, Maria, Waskett, Poppy, Zacharia, Sophie, Cowen, Philip J., and Harmer, Catherine J.
- Subjects
- *
MELATONIN , *EMOTIONS , *ANTIDEPRESSANTS , *SEROTONIN receptors , *DRUG synergism , *PLACEBOS , *SEROTONIN antagonists , *ACETIC acid , *CELL receptors , *CIRCADIAN rhythms , *RESEARCH funding , *HUMAN research subjects , *BLIND experiment , *THERAPEUTICS - Abstract
The antidepressant, agomelatine, has a novel pharmacological profile, with agonist properties at M1 and M2 receptors and antagonist properties at 5HT2C receptors. Whether the antidepressant effects of this treatment are mediated by the drug's effects at the M1 and M2 receptors or the 5HT2C receptor or a synergy between these actions remains unclear. In the present study, a healthy volunteer model of emotional processing, which discriminates between effective and non-effective antidepressant compounds, was used to assess the contribution of melatonin agonism to the efficacy of agomelatine. Fifty-eight healthy volunteers were randomised to receive 7 days of once daily treatment with either 1 mg melatonin, 3 mg melatonin or placebo. Seven days treatment with 3 mg melatonin resulted in earlier bedtimes consistent with a phase advance in circadian rhythm. Some marginal effects of melatonin were observed on emotional processing; however, these were neither consistent with nor comparable to those seen following conventional antidepressant treatment or with agomelatine itself. These data suggest that the antidepressant action of agomelatine cannot be accounted for solely by its action at the M1 and M2 receptors. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
16. Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study.
- Author
-
Taylor, Matthew J, Tiangga, Eleanor R, Mhuircheartaigh, Roísín Ní, and Cowen, Philip J
- Abstract
Ketamine is a N-methyl-D-aspartic acid (NMDA) antagonist that has been associated with temporary clinical improvement in patients with depression. Studies using magnetic resonance spectroscopy (MRS) have shown that major depression is associated with decreased levels of glutamate and glutamine (Glx) in the anterior cingulate cortex, which normalize with clinical recovery. The present study aimed to test whether a ketamine infusion would increase cortical Glx levels in healthy volunteers. Healthy volunteers received an intravenous infusion of ketamine (0.5 mg kg−1, n = 8) or saline (n = 9) over 40 minutes. MRS measurements were obtained at baseline, during, and at the end of the infusion. The infusion of ketamine had significant effects on mental state but there was no effect of ketamine on the levels of Glx (F3,39 = 1.70, p = 0.18) or glutamate (F3,39 = 48, p = 0.70). This study suggests that the gradual infusion of low-dose ketamine in antidepressant doses not cause changes in cortical glutamate or glutamine in healthy volunteers that are visible by proton MRS. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
17. Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing.
- Author
-
Horder, Jamie, Browning, Michael, Di Simplicio, Martina, Cowen, Philip J, and Harmer, Catherine J
- Subjects
- *
RIMONABANT , *CANNABINOID receptors , *MENTAL depression , *ANXIETY , *DRUG side effects - Abstract
Rimonabant is a cannabinoid type 1 receptor (CB1) antagonist formerly used to treat obesity, but which was withdrawn from the market in late 2008 because of its association with psychiatric adverse effects such as depression and anxiety. Previously, we showed that a single dose of rimonabant produced a negative bias on an emotional word memory task, in the absence of subjective mood effects. The present study investigated whether a similar effect on emotional processing could be seen after 7 days’ daily treatment with rimonabant 20 mg, using a randomized, placebo-controlled, between-subjects design in healthy volunteers (final n = 21). In comparison with placebo, rimonabant induced a negative bias on a memory recognition task without producing a change in subjective mood. This raises the possibility that the depressogenic effects of rimonabant may be linked to emotional memory biases, and that such biases may be detectable in the absence of subjective mood changes. Investigating such effects could be useful in detecting adverse psychiatric effects of novel treatments. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
18. Agomelatine facilitates positive versus negative affective processing in healthy volunteer models.
- Author
-
Harmer, Catherine J, de Bodinat, Christian, Dawson, Gerard R, Dourish, Colin T, Waldenmaier, Lara, Adams, Sally, Cowen, Philip J, and Goodwin, Guy M
- Subjects
- *
ANTIDEPRESSANTS , *PSYCHIATRIC drugs , *MENTAL depression , *THERAPEUTICS , *PHARMACOLOGY , *EMOTIONS , *EXPERIMENTAL medicine - Abstract
Agomelatine is a new antidepressant with a novel profile of pharmacological action. The clinical efficacy of agomelatine has been established in major depression, but its actions on emotional bias are unknown. Consequently, the current experimental study assessed the effect of agomelatine on emotional processing in healthy volunteers using an Emotional Test Battery shown to be sensitive to serotonin and noradrenaline reuptake inhibitors. Volunteers were randomized to receive placebo, 25 mg or 50 mg of agomelatine over a 7-day period in a double-blind parallel groups design. Emotional processing (n = 48) was assessed on the morning of day 8 using the Emotional Test Battery which included facial expression recognition, emotional memory, attentional visual probe and emotion-potentiated startle. Mood and subjective state were monitored before and during treatment. Agomelatine (25 mg) decreased subjective ratings of sadness, reduced recognition of sad facial expressions, improved positive affective memory and reduced the emotion-potentiated startle response. The results show that agomelatine has more selective effects on the processing of social facial cues than conventional antidepressants, which could contribute to less blunting of emotional experience. The study highlights the potential value of volunteer models in drug development for screening and profiling of novel antidepressants. [ABSTRACT FROM PUBLISHER]
- Published
- 2011
- Full Text
- View/download PDF
19. Effects of citalopram infusion on the serotonin transporter binding of [11C]DASB in healthy controls.
- Author
-
Hinz, Rainer, Selvaraj, Sudhakar, Murthy, N. Venkatesha, Bhagwagar, Zubin, Taylor, Matthew, Cowen, Philip J., and Grasby, Paul M.
- Subjects
- *
SEROTONIN , *POSITRON emission tomography , *BIOCHEMISTRY , *BRAIN physiology , *BLOOD flow - Abstract
The positron emission tomography (PET) ligand [11C]DASB is currently the most widely used imaging agent for quantitative studies of the serotonin transporter (SERT) in human brain. The aim of this work was to assess the effects of an intravenous infusion of 10 mg citalopram, a selective serotonin reuptake inhibitor (SSRI), before the PET scan on the kinetics of [11C]DASB in arterial plasma and in selected brain regions. Four healthy male volunteers underwent two PET scans with a mean of 523 MBq injected activity after either placebo or citalopram infusion in a randomised design. The citalopram infusion led to a substantial increase of the area under the curve of the metabolite-corrected arterial plasma input function. Total volumes of distribution VT were estimated applying the Logan plot to regional time–activity curves or by generating parametric maps with spectral analysis. A mean reduction of the cerebellar VT of 19% with Logan analysis and of 24% with spectral analysis was observed after citalopram infusion, which confirms previous findings of displaceable SERT ligand binding in cerebellar grey matter. The SERT occupancy for six target regions with moderate to high binding was 60% derived from BPND and 69% derived from BPP.Journal of Cerebral Blood Flow & Metabolism (2008) 28, 1478–1490; doi:10.1038/jcbfm.2008.41; published online 14 May 2008 [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.